摘要
目的评估以米托蒽醌为主的联合化疗方案，治疗成人急性髓细胞性白血病的疗效。方法对本所１９９３年１月～１９９７年１２月住院的成人急性髓细胞性白血病患者（Ｍ３除外），采用以米托蒽醌为主的联合化疗方案进行治疗，共１２６例（１３６例次）。其中初治８５例，难治复发５１例。结果初治组与复发难治组的完全缓解率（ＣＲ）分别为４４．７％，２７．５％；部分缓解率（ＰＲ）２０．０％，９．８％。初治组的早期病死率是４．７％。米托蒽醌的主要副作用是骨髓抑制，由此引起的感染、出血分别为４０．４％，２４．３％；其他非骨髓系统的反应多可耐受，主要表现为肝功能的损害，发生率为３１．８％，多为一过性的转氨酶升高。结论米托蒽醌作为一线药物与其他化疗药物联合对成人急性髓细胞性白血病有较好的疗效，且副作用轻微。
Objective To estimate the effect of mitoxantrone with other chemical agents in treating adult
acute myeloid leukemia. Methods 126 inpatients diagnosed as acute myeloid leukemia
between January 1993 to December 1997 were treated with mitoxantrone with other chemical
agents . 85 had not been treated previously, (untreated ) while 51 were relapsing or resistant to
previous treatment. Results The complete response rate among untreated and the relapsing /
resistant groups were 44.7% and 27.5% ; while the partial response rate were 20.0%, 9.8%
respectively. 4 patients were in the untreated group died early .The main sideeffect of
mitoxantrone is bone marrow depression which led to fever and bleeding with rates of 40.4%,
24.3%. The nonbone marrow sideeffects were tolerable. Damage to the liver was a prominent
occurrence 31.8%. Conclusion mitoxantrone was effective as the first line antitumor drug with
other chemical agents in treating adult acute myeloid leukemia, its sideeffects were mild .
出处
《中华内科杂志》
CAS
CSCD
北大核心
1999年第6期377-379,共3页
Chinese Journal of Internal Medicine
关键词
白血病
急性
米托蒽醌
治疗
Leukemia, mylocytic, acuteMitoxantrone
